Can-Fite BioPharma Ltd. (CANF) Stock Forecast
CANF analyst forecast
as of October 17, 2026- Analyst consensus
- Strong buy 5.00 / 5 from 2 analysts
- Price target
- $8.00 average of analyst targets
- Upside to target
- +354.5% from the latest close
- Next earnings
- —
- 52-week range
- $1.76 – $10.32
CANF analyst ratings
2 analystsNumber of analysts at each rating.
CANF price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
CANF earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current fiscal year (2026) | −$2.04 | −$2.04 | −$2.04 | −$11.94 | +83.5% | 1 |
| Next fiscal year (2027) | −$0.91 | −$0.91 | −$0.91 | −$2.04 | +55.4% | 1 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
CANF revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | — | — |
| Current fiscal year (2026) | $404,000 | $404,000 | $404,000 | −0.2% | 1 |
| Next fiscal year (2027) | $404,000 | $404,000 | $404,000 | 0.0% | 1 |
CANF EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
CANF revenue: reported and forecast
CANF EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current fiscal year (2026) | −$1.04 | −$0.68 | −$0.68 | −$0.68 | −$2.04 | +96.2% | 1 up · 0 down |
| Next fiscal year (2027) | −$0.26 | −$0.27 | −$0.27 | −$0.27 | −$0.91 | +250.0% | 0 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
CANF earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; CANF beat in 7 of 12.
What analysts expect from CANF
2 analysts cover Can-Fite BioPharma; their consensus rating is strong buy (5.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $8.00, 354.5% above the latest close of $1.76. Analysts expect earnings of −$2.04 per share for 2026, +83.5% from a year earlier. For 2027 the average estimate is −$0.91 per share on revenue of $0.4 million. Can-Fite BioPharma beat the EPS estimate in 7 of the last 12 quarters.
Related: CANF income statement, CANF key metrics, CANF chart. See the CANF stock overview for the latest quote and news.
CANF forecast FAQ
What is Can-Fite BioPharma's price target?
The average analyst price target for Can-Fite BioPharma is $8.00, 354.5% above the latest close of $1.76.
Is Can-Fite BioPharma a buy, hold or sell?
Of 2 analysts covering Can-Fite BioPharma, 2 rate it a strong buy, 0 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Can-Fite BioPharma's EPS forecast?
Analysts forecast −$2.04 per share for 2026 (range −$2.04 to −$2.04); for 2027 the estimate is −$0.91.
What is Can-Fite BioPharma's revenue forecast?
The average revenue estimate for 2026 is $0.4 million, growth of −0.2%; for 2027 it is $0.4 million.
Does Can-Fite BioPharma usually beat earnings estimates?
Can-Fite BioPharma reported EPS at or above the analyst estimate in 7 of the last 12 quarters.